NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis $10.90 -0.50 (-4.39%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.81▼$11.3550-Day Range$10.90▼$17.6052-Week Range$9.00▼$22.33Volume159,958 shsAverage Volume186,063 shsMarket Capitalization$359.10 millionP/E RatioN/ADividend YieldN/APrice Target$22.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Lexeo Therapeutics alerts: Email Address Lexeo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside103.1% Upside$22.14 Price TargetShort InterestBearish8.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.01Based on 3 Articles This WeekInsider TradingSelling Shares$502,638 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.74) to ($2.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector322nd out of 910 stocksBiological Products, Except Diagnostic Industry46th out of 155 stocks 4.6 Analyst's Opinion Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexeo Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lexeo Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.84% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 16.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXEO. Previous Next 2.8 News and Social Media Coverage News SentimentLexeo Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lexeo Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $502,638.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexeo Therapeutics are expected to grow in the coming year, from ($2.74) to ($2.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexeo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Lexeo Therapeutics Stock (NASDAQ:LXEO)Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Read More LXEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXEO Stock News HeadlinesAugust 15, 2024 | insidertrades.comRichard Nolan Townsend Sells 5,000 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) StockSeptember 5 at 7:30 AM | globenewswire.comLexeo Therapeutics to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...September 2, 2024 | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Sees Significant Growth in Short InterestAugust 28, 2024 | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by BrokeragesAugust 21, 2024 | finance.yahoo.comLexeo Therapeutics, Inc. (LXEO)August 14, 2024 | markets.businessinsider.comBuy Rating for Lexeo Therapeutics Backed by Strong Finances and Promising Clinical TrialsAugust 14, 2024 | markets.businessinsider.comBuy Rating on Lexeo Therapeutics: Promising Clinical Advancements and Strategic FDA EngagementSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 12, 2024 | globenewswire.comLexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational HighlightsJuly 19, 2024 | markets.businessinsider.comPromising Interim Clinical Trial Results Bolster Confidence in Lexeo Therapeutics’ Gene Therapy PotentialJuly 19, 2024 | markets.businessinsider.comLexeo Down Despite Upbeat Rare Disease Gene Therapy DataJuly 15, 2024 | globenewswire.comLexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyJuly 8, 2024 | globenewswire.comLexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of DirectorsMay 9, 2024 | globenewswire.comLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsMay 7, 2024 | globenewswire.comLexeo Therapeutics to Participate in Upcoming Investor ConferencesApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy AdvancementsApril 24, 2024 | uk.investing.comLexeo Therapeutics secures rights to advance gene therapySee More Headlines Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)12/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CUSIPN/A CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$22.14 High Stock Price Target$28.00 Low Stock Price Target$19.00 Potential Upside/Downside+103.1%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($22.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.43% Return on Assets-51.50% Debt Debt-to-Equity Ratio0.01 Current Ratio9.38 Quick Ratio9.38 Sales & Book Value Annual Sales$650,000.00 Price / Sales552.46 Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book2.18Miscellaneous Outstanding Shares32,945,000Free Float31,462,000Market Cap$359.10 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. R. Nolan Townsend (Age 43)CEO & Director Comp: $864.34kDr. Eric Adler M.D. (Age 50)Chief Medical Officer & Head of Research Comp: $623.4kMs. Jenny R. Robertson (Age 49)Chief Business & Legal Officer Comp: $617.9kDr. Ronald G. Crystal M.D.Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardDr. Paul B. McCormac Ph.D. (Age 54)Chief Technical Officer Comp: $471.73kDr. Jordan Shin M.D.Ph.D., Senior Vice President of Clinical Development & Translational Science, CardiologyDr. Jordan S. Dubow M.D. (Age 45)Head of CNS Clinical Development Dr. Sandi See Tai M.D. (Age 53)Chief Development Officer Mr. Ryan McHenryVP & Corporate ControllerMore ExecutivesKey CompetitorsKura OncologyNASDAQ:KURAArcus BiosciencesNYSE:RCUSCentessa PharmaceuticalsNASDAQ:CNTANewAmsterdam PharmaNASDAQ:NAMSCassava SciencesNASDAQ:SAVAView All CompetitorsInsiders & InstitutionsNovo Holdings A SSold 187,798 shares on 8/20/2024Ownership: 4.403%Richard Nolan TownsendSold 5,000 sharesTotal: $57,650.00 ($11.53/share)Rhumbline AdvisersBought 3,627 shares on 8/1/2024Ownership: 0.041%Bank of New York Mellon CorpBought 3,483 shares on 7/26/2024Ownership: 0.097%Richard Nolan TownsendSold 26,969 sharesTotal: $444,988.50 ($16.50/share)View All Insider TransactionsView All Institutional Transactions LXEO Stock Analysis - Frequently Asked Questions How have LXEO shares performed this year? Lexeo Therapeutics' stock was trading at $13.42 at the beginning of 2024. Since then, LXEO shares have decreased by 18.8% and is now trading at $10.90. View the best growth stocks for 2024 here. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.64). When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $100 million in an initial public offering on Friday, November 3rd 2023. The company issued 9,090,910 shares at $11.00 per share. Who are Lexeo Therapeutics' major shareholders? Top institutional investors of Lexeo Therapeutics include Novo Holdings A S (4.40%), Bank of New York Mellon Corp (0.10%) and Rhumbline Advisers (0.04%). Insiders that own company stock include Fund Vi LP Omega and Richard Nolan Townsend. View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LXEO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
